Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, ...

Kailera is building out a weight-loss drug pipeline with both injectables and pills, with four candidates in various trial ...

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and ...

Chandan Taparia has recommended three stocks to buy today, 15 May 2026 - National Aluminium Company, Apollo Hospitals ...

Olema Pharmaceuticals awaits Phase 3 breast cancer data in fall 2026, with $505M in cash to fund catalysts. Learn why OLMA ...

Pfizer (NYSE:PFE | PFE Price Prediction) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at ...

Top 10 mid-cap stocks by YTD performance amid market volatility—see 600%+ gainers across semis, biotech & more, plus mid-cap ...

Stifel upgrades RXO to buy from hold Stifel said its sees "idiosyncratic levers" for the asset-light transportation company. ...

It's no longer a secret that the Teva Pharmaceutical Industries (NYSE: TEVA) of the past is no more. The Israel-based company ...

Top picks include a consensus buy on NMDC, alongside Zydus Lifesciences, Varun Beverages (VBL), Max Healthcare, and Tata ...

ICICI Direct maintained a 'Buy' rating with a target price of Rs 5,750. The firm highlighted that revenues grew, driven by established power brands such as Eliquis, Magnex, and Meronem.